Search research articles
Contact Us
Filters
Showing results (111-120 of 166) with videos related to
Page
of 17
Sort By:
Hepatology (Baltimore, Md.)
|
August 13, 2008
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin
Michael W Fried, Donald M Jensen, Maribel Rodriguez-Torres, et al.
Gastroenterology
|
August 8, 2006
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
Hari S Conjeevaram, Michael W Fried, Lennox J Jeffers, et al.
Alimentary Pharmacology & Therapeutics
|
October 25, 2021
Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis
Hannah P Kim, Michael O Idowu, Andrea R Mospan, et al.
American Journal of Epidemiology
|
May 20, 2017
Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B
Mohamed A Hassan, W Ray Kim, Ruosha Li, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 26, 2011
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C
Sarah J Schrieber, Roy L Hawke, Zhiming Wen, et al.
Gastroenterology
|
June 16, 2010
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
Alexander J Thompson, Jacques Fellay, Keyur Patel, et al.
Journal of Hepatology
|
June 25, 2003
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C
Stefan Zeuzem, E Jenny Heathcote, Mitchell L Shiffman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 12, 2019
Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection
Mayur Brahmania, Manuel Lombardero, Bettina E Hansen, et al.
Journal of Hepatology
|
September 15, 2014
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET
Stuart C Gordon, Andrew J Muir, Joseph K Lim, et al.
Journal of Viral Hepatitis
|
January 17, 2025
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy
Amit G Singal, K Rajender Reddy, Massimo Colombo, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 166) with videos related to
Sort By:
Page
of 17
Hepatology (Baltimore, Md.)
|
August 13, 2008
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin
Michael W Fried, Donald M Jensen, Maribel Rodriguez-Torres, et al.
Gastroenterology
|
August 8, 2006
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
Hari S Conjeevaram, Michael W Fried, Lennox J Jeffers, et al.
Alimentary Pharmacology & Therapeutics
|
October 25, 2021
Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis
Hannah P Kim, Michael O Idowu, Andrea R Mospan, et al.
American Journal of Epidemiology
|
May 20, 2017
Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B
Mohamed A Hassan, W Ray Kim, Ruosha Li, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 26, 2011
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C
Sarah J Schrieber, Roy L Hawke, Zhiming Wen, et al.
Gastroenterology
|
June 16, 2010
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
Alexander J Thompson, Jacques Fellay, Keyur Patel, et al.
Journal of Hepatology
|
June 25, 2003
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C
Stefan Zeuzem, E Jenny Heathcote, Mitchell L Shiffman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 12, 2019
Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection
Mayur Brahmania, Manuel Lombardero, Bettina E Hansen, et al.
Journal of Hepatology
|
September 15, 2014
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET
Stuart C Gordon, Andrew J Muir, Joseph K Lim, et al.
Journal of Viral Hepatitis
|
January 17, 2025
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy
Amit G Singal, K Rajender Reddy, Massimo Colombo, et al.
Page
of 17